Tilray Reports Mixed Q1 Results; Reaffirms FY27 Outlook
Tilray (TLRY) reported mixed first-quarter results with a non-GAAP EPS of $0.02, which beat expectations by $0.16 per share. However, revenue came in at $257.15 million, missing estimates by $9.65 million and showing year-over-year growth of 22.7%. The company highlighted strong performance from its international business, particularly the EMEA region where revenue increased by 71%, driven primarily by medical cannabis, beverage, and pharmaceutical distribution segments. Despite underperforming on revenue, Tilray reaffirmed its full-year FY27 outlook, signaling confidence in future growth. Management attributed the Q1 results to continued progress across key markets and strategic initiatives aimed at expanding global operations.
Tickers: $TLRY